New National Cholesterol Education Program III Guidelines for Primary Prevention Lipid-Lowering Drug Therapy
Open Access
- 15 January 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 105 (2), 152-156
- https://doi.org/10.1161/hc0202.101971
Abstract
Background— The guidelines in the Third Report of the National Cholesterol Education Program (NCEP III) include absolute risk and lower LDL cholesterol (LDL-C) levels to assess eligibility for lipid-lowering drug therapy. We studied the impact of these changes on the size, sex, and age distribution of the target US population using data from the Third Annual National Health and Nutrition Survey (NHANES III) (1988 to 1994).Keywords
This publication has 7 references indexed in Scilit:
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Prevention of coronary heart disease in clinical practice Recommendations of the Second Joint Task Force of European and other Societies on Coronary PreventionEuropean Heart Journal, 1998
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJAMA, 1998
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)JAMA, 1993
- Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative UltracentrifugeClinical Chemistry, 1972